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Abstract
Background: In the current Ebola epidemic in Western Africa, many healthcare workers have become infected.
Some of these have been medically evacuated to hospitals in Europe and the USA. These clinical experiences
provide unique insights into the course of Ebola virus disease under optimized condition within high level isolation
units.
Case presentation: A 50-year-old Caucasian male physician contracted Ebola virus diseases in Sierra Leone and
was medically evacuated to Italy. Few days after the admission the course of the illness was characterized by severe
gastro-intestinal symptoms followed by respiratory failure, accompanied by pulmonary infiltration and high Ebola
viral load in the bronchial aspirate and Plasmodium vivax co-infection. The patient received experimental antiviral
therapy with favipiravir, convalescent plasma and ZMAb. Ebola viral load started to steadily decrease in the blood
after ZMAb administration and became undetectable by day 19 after admission, while it persisted longer in urine
samples. No temporal association was observed between viral load decay in plasma and administration of
favipiravir. The patient completely recovered and was discharged 39 days after admission.
Conclusions: This is the first case of Ebola-related interstitial pneumonia documented by molecular testing of lung
fluid specimens. This reports underlines the pivotal role of fluid replacement and advanced life support with
mechanical ventilation in the management of patients with Ebola virus diseases respiratory failure. Beside our finding
indicates a close temporal association between administration of cZMAb and Ebola virus clearance from blood.
Keywords: Hemorrhagic fever, Ebola, Pneumonia, viral, Malaria, vivax, Immunization, passive, Antibodies, monoclonal,
Favipiravir, Fluid therapy, Life support care, Hospitals, isolation
Background
Since December 2013, the Ebola virus (EBOV) Makona
variant has been gripping Western Africa [1]. Over this
time the epidemic has exponentially grown and has
moved to Europe and North America, with several
imported cases and even few clusters of local transmis-
sion [2, 3]. An unprecedented number of healthcare
workers (HCWs) from different countries have been
infected, some of whom died [4]. In total 26 cases of
Ebola virus diseases (EVD), 4 of which fatal [5], have
been treated in Europe [6–8] and North America [9, 10]
since the beginning of the outbreak.
Hereby we describe the successful management of a
50-year-old Italian male physician who contracted Ebola
virus disease (EVD) while working in an Ebola Treat-
ment Unit in Sierra Leone. The course of infection was




A 50-year-old male physician contracted Ebola virus dis-
ease (EVD) while working in Sierra Leone. He had
joined the Ebola treatment center on September 2014
and on November 20, he developed a single episode of
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vomiting, diarrhea and fever (37.5 °C). He had no history
of previous malaria episode and a malaria antigen rapid
test was negative. On November 24 he started artemisinine
combined therapy, despite the negative rapid test for
malaria. On this same day he tested positive to a molecular
assay for Ebola virus (EBOV) and was medically evacuated
to the Lazzaro Spallanzani National Institute for Infectious
Diseases in Rome, by an Italian military flight [11]. At
arrival (November 25) he was febrile and complained with
severe fatigue but self-sufficient. He was admitted to a
medical high level isolation unit specifically devoted for
caring for patients with highly infectious diseases [12].
Table 1 reports patient’s signs and symptoms timeline.
Figures 1, 2 and 3 reports EBOV viral load, blood counts
and clinical chemistry, respectively. A detailed description
of all laboratory assays is reported in Additional file 1.
The timeline of patient’s clinical course is reported in
Additional file 2.
Clinical findings during hospital stay
Admission in medical isolation unit
The patient remained in the medical isolation unit be-
tween November 25 and December 4, 2014. Patients’
clinical presentation was dominated by fever and gastro-
intestinal symptoms. At arrival he received fluid therapy,
empiric antibiotic therapy and favipiravir. On November
26, therapy with convalescent plasma from one survivor
of the present EBOV outbreak was given, the adminis-
tration was followed by retrosternal chest pain, high
fever, chills and low oxygen saturation resolving after
hydrocortisone and clorfenamine administration. On
November 28, a measles-like rash appeared on head, trunk
and limbs and was accompanied by nausea and vomiting.
On November 29, alanine amino transferase (ALT) con-
centration suddenly increased, while renal function and
coagulation remained normal. Then we decided to sus-
pend favivpiravir administration. November 30, the patient
underwent a second administration of convalescent
plasma from a different donor. Eventually patient received
melanocortin [13] (a peptide for controlling “cytokine
storms” and preventing vascular leakage syndrome) and
steroids. The following day respiratory function gradually
worsened and chest X-rays performed on December 2
showed bilateral interstitial pulmonary infiltrates (Fig. 4).
On December 3, the patient received ZMAb [14, 15] a
mixture of monoclonal antibody against EBOV glycopro-
tein. The administration was followed by a sharp reduc-
tion of the EBOV blood level. The same day due to
progressive onset of severe respiratory failure the patient
was moved to the intensive care unit (ICU).
Admission in ICU
The patient was cared for in the ICU between December
4 and 11. This unit meets requirement for high level bio-
containment [12, 16]. Soon after admission, he underwent
mechanical ventilation and a three-way central venous
catheter (CVC) was inserted into the right internal jugular
vein. A urinary catheter and a naso-gastric tube were also
inserted.
While intubated, the patient underwent lung ultra-
sounds (Nanomaxx Sonosite®) according to Bedside
Lung Ultrasound in Emergency (BLUE) protocol [17].
Pleural effusion and pneumothorax were ruled out, but
the presence of up to four B-lines in all the standard
points suggested a significant lung interstitial involve-
ment. A progressive bilateral reduction in the number of
B-lines, initially in the upper and lower BLUE points,
and later in the posterolateral alveolar or pleural syn-
dromes point, was observed during the ICU stay.
On December 5, he received a second dose of ZMAb
followed by a second sharp decrease of EBOV viremia.
On December 6, due to severe non-bloody diarrhea, a
rectal fecal collector (Flexiseal® ConvaTec) was placed.
On December 7, due to persisting fever another malaria
test (PCR) was performed which yielded a positive re-
sults for P. vivax infection. Therefore anti-malaria ther-
apy was started. On December 9, the patient underwent
a bronchial aspirate; PCR on bronchial aspirate fluids
evidenced a viral load of 6.88 Log copies of EBOV RNA/
ml. All PCRs for other viral and bacterial respiratory
pathogens were negative (see Additional file 1). On De-
cember 10, the patient was extubated and moved to the
medical isolation unit one day later.
Recovery and discharge
After readmission to the medical isolation unit the clin-
ical conditions gradually improved. On December 11, all
antimicrobials were suspended considering the improve-
ment of general conditions and persistent lack of posi-
tive cultural and molecular test for bacteria and fungi
(Additional file 1). Since December 14 fever completely
disappeared. On December 17, CVC, urinary catheter
and rectal fecal collector were also removed. On Decem-
ber 21, the patient completely recovered.
A progressive increase of the anti-EBOV IgM titer was
observed from December 11, reaching a peak of 1:160
on December 25. The anti-EBOV IgG titer was stably at
1:160 until December 25, presumably as the result of
convalescent plasma administration, and eventually in-
creased until discharge. The patients was discharged on
January 2 after that two consecutive negative EBOV
PCR assay results from blood, urine, sweat (axillary
swab) and stool were obtained (see Fig. 1).
Therapeutic intervention
General supportive therapy
The patient received 4-5 L/day of intravenous hydration
with crystalloid solution since admission for 18 days.
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The amount and composition of the solution were based
on the daily plasma determination of electrolytes, venous
pH and daily fluid output. Between November 28 and
December 4, he received parenteral nutrition and,
eventually, enteral nutrition between December 5 and 11
(approximately 2000 kCal/day). Between December 4
and 11, he received norepinephrine (0.05 mcg/kg/min)
and furosemide (20 mg tid).
Table 1 Patients clinical parameters during hospital stay
Day Place of stay Diarrhea a fi02 (%) S02 (%) Fever (°C) HR (beat/min) Vomit (episode) BP (mmHg)
25/11/2014 Medical Yes 21 98 39.1 80 0 50/100
26/11/2014 Medical Yes 50 95 38.4 89 0 80/120
27/11/2014 Medical Yes 21 96 37.4 60 0 90/135
28/11/2014 Medical Yes 21 97 39.4 131 8 70/120
29/11/2014 Medical Yes 40 95 39.4 80 3 80/150
30/11/2014 Medical Yes 40 95 39.1 70 3 90/145
01/12/2014 Medical Yes 40 91 38.8 75 2 90/150
02/12/2014 Medical Yes 50 90 39.4 80 2 80/140
03/12/2014 Medical Yes 50 90 b 38.4 64 2 80/130
04/12/2014 ICU Yes 60 87 c 37.8 70 2 80/130
05/12/2014 ICU Yes 50 93 c 37.4 120 0 70/110
06/12/2014 ICU Yes 40 91 c 39.2 110 0 70/105
07/12/2014 ICU 1300 40 92 c 37.8 105 0 70/115
08/12/2014 ICU 2100 30 93 c 36.5 95 0 65/110
09/12/2014 ICU 3300 30 93 d 37.5 100 0 75/120
10/12/2014 ICU 1700 35 92 38 95 0 85/130
11/12/2014 ICU 1500 31 94 37.8 95 0 80/120
12/12/2014 Medical 1700 35 97 38.1 110 2 90/150
13/12/2014 Medical 1000 35 98 37.4 110 1 80/110
14/12/2014 Medical 500 28 98 36.8 95 0 80/120
15/12/2014 Medical 300 28 99 36.5 90 0 70/110
16/12/2014 Medical Na 21 98 36.6 90 0 85/130
17/12/2014 Medical Na 21 98 36.0 85 0 80/120
18/12/2014 Medical Na 21 98 36.3 80 0 70/110
19/12/2014 Medical Na 21 98 36.9 78 0 80/120
20/12/2014 Medical Na 21 98 36.5 75 0 80/120
21/12/2014 Medical Na 21 98 37.0 70 0 70/110
22/12/2014 Medical Na 21 98 36.4 70 0 90/130
23/12/2014 Medical Na 21 98 36.6 70 0 80/120
24/12/2014 Medical Na 21 98 36.5 70 0 75/110
25/12/2014 Medical Na 21 98 36.5 70 0 80/120
26/12/2014 Medical Na 21 98 36.5 70 0 70/130
27/12/2014 Medical Na 21 98 36.4 70 0 80/130
28/12/2014 Medical Na 21 98 36.5 70 0 90/130
29/12/2014 Medical Na 21 98 36.4 70 0 70/120
30/12/2014 Medical Na 21 98 36.5 70 0 80/110
31/12/2014 Medical Na 21 98 36.5 70 0 90/130
01/01/2015 Medical Na 21 98 36.5 70 0 80/120
02/01/2015 Medical Na 21 98 36.5 70 0 70/110
a Diarrhea amount was provided in ml between 7 and 15 December while the rectal collector was in place; b: 66 % on air (Fi02 21 %); c: under mechanical
ventilation; d: extubated; na: not any
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Antimicrobials
The patient received empiric antibiotic treatment for
18 days since admission. On November 25, he started
ceftriaxone (2000 mg daily) and oral levofloxacin
(500 mg bid). On November 28, ceftriaxone and levo-
floxacin were stopped due to the onset of severe diar-
rhea and increase of liver enzymes. Meropenem
(1000 mg tid i.v.) plus metronidazole (500 mg qid i.v.)
were started. On December 4, due to the persistence of
fever and diarrhea, meropenem and metronidazole were
discontinued and anidulafungin (200 mg as a loading
dose and then 100 mg daily i.v.), piperacillin/tazobactam
(4500 mg qid i.v.), linezolid (600 mg bid i.v.) and oral
vancomycin (125 mg qid) were started. Oral vancomycin
was discontinued after a negative Clostridium difficile PCR
assay on stools. On December 9, piperacillin/tazobactam
and linezolid were discontinued, and metronidazole
(500 mg qid i.v.) was started.
Anti-malarial therapy
Anti-malarial therapy with chloroquine (600 mg time 0
and then 300 mg after 6, 24 and 48 h) was given through
a nasogastric tube. Primaquine was prescribed for future
use after G6PDH determination following discharge.
Melanocortin
Melanocortin (TCS 10) [13] was administered to prevent
plasma leakage syndrome; two 10 mg i.v. bolus 1 h apart
from each other, followed by a 6 h continuous infusion
of 50 mg in 60 ml of 0.9 % NaCl solution.
Favipiravir
The oral RNA polymerase inhibitor favipiravir [18–20]
was administered orally for four days: loading dose in 3
fractionated doses (2400 mg followed by 2400 mg and
then 1200 mg), then 1200 mg bid (cumulative dose
9,600 mg).
Convalescent plasma
The first course of convalescent plasma consisted in a
250 ml unit of a compatible blood group plasma to be
administered with paracetamol and clorfenamine pre-
medication. Due to insurgence of an adverse reaction
oxygen therapy (50 % Fi O2) and 500 mg hydrocortisone
plus clorfenamine 10 mg were given i.v. infusion for 2
subsequent days.
The second course of convalescent plasma consisted
in a 250 ml unit of a compatible blood group plasma
from a different donor that was administered after pre-
medication with paracetamol, clorfenamine and 500 mg
metylprednisolone. In this case no adverse reaction was
reported.
ZMAb
Monoclonal antibodies were diluted, filtered with a
0.22 μm filter and topped with 0.9 % NaCl solution to a
final volume of 1000 ml. After premedication with 1 mg/kg
methyl prednisolone, ZMAb was infused in 12-15 h via a
peripheral line. No adverse reactions were observed.
Fig. 1 EBOV viral load in different clinical specimen and time of administration of experimental antiviral therapies
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Discussion
We reported the case of a 50-year-old Italian physician
with severe EVD due to EBOV Makona variant, compli-
cated with severe interstitial pneumonia and P. vivax co-
infection. He received prompt fluid replacement and
electrolyte supplementation to prevent volume depletion,
metabolic disorders and hypovolemic shock [21, 22]. He
was finally discharged in good clinical conditions 39 days
after admission.
Upon admission, the patient presented with severe
lymphopenia and moderate low platelet count compat-
ible with EBOV infection [23] and P. vivax co-infection.
On day 5 after admission, a sudden and sharp increase
of WBC and platelets occurred, likely due to exogenous
steroid administration and to melanocortin-induced en-
dogenous glucocorticoid production [24].
Severe interstitial lung involvement was the main com-
plication. Chest X-rays, lung ultrasounds and the high
Fig. 2 Blood counts during hospital stay. ICU= intensive care unit; WBC= white blood cells; Neu.= neutrophils; Lym.=lymphocytes; Mono.= Monocytes;
PLTS= platelets; HB= hemoglobin
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EBOV RNA concentration in the bronchial aspirate were
strongly suggestive of EBOV-related interstitial pneumo-
nia. Other authors reported respiratory failure in EVD
possibly due to vascular leakage [7] and transfusion re-
lated acute lung injury (TRALI) [8]. However, we believe
that vascular leakage was unlikely in this case because of
the lack of both multi-organ involvement and coagula-
tion abnormalities, that characterize vascular leakage
syndrome [7, 25]. In addition the presence of high
EBOV RNA load in the lower respiratory tract
Fig. 3 Clinical chemistry assays during hospital stay (all tests were performed on venous blood specimens). ICU= intensive care unit; GLU= glucose;
ALT= alanine transaminase; BIL.= bilirubin; CREA.= creatinine; BUN.= blood urea nitrogen; Na+= sodium ; K+= potassium; INR= international
normalized ratio
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secretions, in the absence of detection of other common
respiratory pathogens, supports the hypothesis that
EBOV could have directly contributed to the lung dam-
age. In fact, it is unlikely that the EBOV RNA detected
in bronchial aspirate fluids could represent a trivial re-
sult of spill over from the blood compartment, eventu-
ally accompanied by delayed clearance, since the
concomitant blood sample showed barely detectable
EBOV RNA, and the blood concentration in the previ-
ous 3 days was 2.58-3.29 Log lower than the concentra-
tion in the bronchial aspirate. The most likely
explanation for these findings is that the virus actually
replicated into the lower respiratory tract. Noteworthy,
direct viral involvement in lung injury has been already
suggested in patients who received care in the USA [10].
Moreover, the hypothesis that the EBOV can actually
replicate into lungs is supported by a recently published
review which collect results of post mortem examina-
tions from 89 cases of fatal filoviral infections in humans
(24 of which with EBOV). This analysis provides evi-
dence for viral replication in lungs by demonstrating
viral antigens in several lung tissues and the presence of
EBOV nucleic acids in resident macrophages [26].
Whether the P. vivax co-infection might have contrib-
uted to the lung injury can be hardly ascertained; how-
ever, acute respiratory distress syndrome is a frequent
clinical feature in the rare circumstance of fatal P.vivax
infection [27].
In our opinion, mechanical ventilation was crucial for
survival in our patient because supported respiratory
function and prevented muscular exhaustion, which
allowed the patient to recover from the acute lung injury.
This underlines that prompt access to advanced life sup-
port provides a substantial clinical benefit in EVD [28].
Despite 3 negative malaria antigen assays, the patient
eventually tested positive in a PCR assay for P. vivax.
Malaria co-infection was recently reported in an EVD
patient who received care in the USA [9]. Our
experience highlights that malaria antigen assays may
offer an incomplete diagnostic picture leading to sub-
optimal clinical management. Consequently, patients
with EVD returning from areas endemic for malaria
should receive empirical malaria treatment if neither
molecular or microscopy assays are available or if con-
cerns on malaria are raised.
Our patient also received empirical therapy against
bacteria, fungi and intestinal protozoa. Severe bacterial
super-infection has already been reported in subjects
who received care for EVD in Europe [6]. At present,
there is no definitive evidence to predict the actual risk
of microbial super-infection in EVD patients. Neverthe-
less, we feel that the use of anti-infective drugs is a pru-
dent approach. In fact, EVD patients may develop severe
infective complications as the consequence of bacteria
translocation from the gut [6], from equipment used for
parenteral nutrition [29] or co-infection with tropical in-
testinal protozoa [30].
Our patient received three different experimental anti-
viral treatment, including favipiravir, convalescent plasma
and ZMAb.
Favipiravir was given for 4 days. During this time, the
patient experienced worsening of gastrointestinal symp-
toms, and an increased of ALT and bilirubin levels. This
report provides no evidence of any causative association
between favipiravir and either potential adverse events
or viral load variation. In particular, gastrointestinal and
liver abnormalities may be the consequence of P. vivax
and EBOV infections. In fact, data from uncontrolled
studies in EBOV-confirmed that patients did not report
significant hepatic or gastrointestinal toxicity for similar
favipiravir dosages but fail in providing any conclusive
evidence on drugs efficacy [31, 32].
The two administrations of convalescent plasma were
associated with a decrease viral load of 2.10 and 0.80
Log RNA copies/ml, respectively. The adverse event
after the first plasma administration may have been due
to an immune reaction to factors of the unknown donor
and/or the lack of premedication with steroids. The pos-
sible influence of such adverse reaction on lung injury
cannot be ruled out. Nevertheless, transfusion related
acute lung injury (TRALI) could have hardly had a pri-
mary role. In fact, TRALI is an acute event which occurs
within 6 h after transfusion [33]. In contrast our patients
had lung function significantly worsened only since
December 3, this is 7 and 3 days after the first and sec-
ond convalescent plasma transfusion, respectively. Be-
side the two plasma donors (one of whom was a female)
had no history of blood transfusions or previous preg-
nancies, which reduce possibility of TRALI [33].
Administration of ZMAb [14, 15] was temporally asso-
ciated with a sharp and sustained decay of plasma viral
load. As the increase of IgM and IgG was observed after
Fig. 4 Chest XR carried out on December 2 2014. SN= left side; the
white square was added for patient’s privacy protection
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the start of viremia decay, it is unlikely that the en-
dogenous antibody response could be responsible for the
observed decay of EBOV RNA, although the administra-
tion of convalescent plasma is a major confounder. The
potential beneficial effect of monoclonal antibody ther-
apy against EVD was reported in a recent experience
describing the clinical management of few EVD patients
treated with ZMapp (a similar, though not identical
compound) [9, 10]. Interestingly, monoclonal antibody
therapy against EBOV is one of only two clinical inter-
ventions capable of decreasing viral loads and significantly
reduce the mortality of non-human primates infected with
EBOV in controlled conditions [34]. Although, no causal
association between administration of ZMAb and the
patient’s outcome can be inferred; in fact, the viral decay
load might have been coincidental rather than due to the
ZMAb administration.
Conclusion
This report describes the successful management of a
patient with severe EVD in a setting with high health-
care standards. Several issues emerge from our experi-
ence. Firstly, fluid replacement and advanced life
support with mechanical ventilation were pivotal for the
patient’s recovery, and in our opinion, all patients with
EVD should have access to this level of care. Secondly, it
is prudent to start empirical therapy for malaria in the
absence of reliable testing, such as PCR assays. Finally,
similarly to other individual experiences, we observed a
close temporal association between administration of
ZMAb and viral load decay, suggesting that clinical and
translational research on these new promising molecules
should be prioritize.
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Written informed consent was obtained from the patient
for publication of this Case report and any accompany-
ing images.
The INMI’s Institutional Ethical Board assessed the
criteria for access to experimental drugs and invasive
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cedure or treatment performed, after thoroughly explan-
ation of reasonably anticipated benefits and potential
hazards of intervention.
Emergency Use Authorization for investigational new
drugs was issued by the Italian Drug Agency (AIFA), the
authority entitled to approve medical agents to be used
for therapy of disease when they are not the standard of
care or supported by research that proves their safety.
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